Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility

Simply Wall St.01-10

BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602307155?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-10 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602307155","market":"sg","top_or_hot":-1,"title":"Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility","media":"Simply Wall St.","content":"<div>\n<p>BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 06:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1","article_id":"2602307155","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-rece-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602307155","pubTimestamp":1767997119,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance and ongoing drug development firmly in focus.\nSee our latest analysis for BioCryst Pharmaceuticals.\nRecent trading has been a bit choppy, with a 1 day share price return of a 3.79% decline and a 7 day share price return of a 2.31% decline, while the 90 day share price return of 5.54% contrasts...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药","BK4547":"WSB热门概念","BK4139":"生物科技"},"translate_title":"在近期股价波动后评估BioCryst Pharmaceuticals(BCRX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1.5},"content_text":"BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent share price moves, with the stock last closing at US$7.62. For a rare disease focused biotech, that puts current performance and ongoing drug development firmly in focus. See our latest analysis for BioCryst Pharmaceuticals. Recent trading has been a bit choppy, with a 1 day share price return of a 3.79% decline and a 7 day share price return of a 2.31% decline, while the 90 day share price return of 5.54% contrasts with a 1 year total shareholder return of a 5.34% decline. This suggests short term momentum has picked up even as longer term holders have experienced weaker overall outcomes. If BioCryst’s moves have caught your eye, it could be a good moment to broaden your search across rare disease and biotech names using healthcare stocks. With BioCryst trading at US$7.62 alongside an intrinsic discount flag and a value score of 5, the key question is whether the current price underestimates its rare disease pipeline or whether the market is already pricing in future growth. AdvertisementMost Popular Narrative: 63% Undervalued With BioCryst closing at US$7.62 against a narrative fair value of US$20.60, the valuation gap is wide and built on detailed growth assumptions.  Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.  Read the complete narrative. Curious how this rare disease thesis gets to that higher fair value? The heart of the narrative is faster revenue growth, sharply higher margins, and a richer future earnings multiple. Want to see the specific earnings and valuation targets behind that view. Result: Fair Value of $20.60 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat narrative still faces real tests, including BioCryst’s heavy reliance on ORLADEYO, as well as execution risks around the US$700m Astria acquisition and navenibart’s Phase 3 program. Find out about the key risks to this BioCryst Pharmaceuticals narrative.  Build Your Own BioCryst Pharmaceuticals Narrative If you see the story differently or prefer to weigh the assumptions yourself, you can build a custom view in just a few minutes using Do it your way. A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If BioCryst has sparked your interest, do not stop here. Use the tools available to widen your watchlist and spot opportunities you might otherwise miss.  Target potential mispricings by scanning these 878 undervalued stocks based on cash flows that currently trade below what their cash flows may justify. Ride major technology shifts early by tracking these 28 AI penny stocks shaping how artificial intelligence reaches real world products and services. Strengthen your income focus by zeroing in on these 11 dividend stocks with yields > 3% that could complement growth oriented positions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602307155","isCrawlerRequest":true}